Guggenheim Cuts Valneva (NASDAQ:VALN) Price Target to $15.00

Valneva (NASDAQ:VALN) had its target price trimmed by Guggenheim from $17.00 to $15.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Valneva in a report on Friday, March 21st.

Valneva Stock Up 1.3 %

Valneva stock opened at $7.16 on Monday. The business’s 50-day simple moving average is $6.51 and its two-hundred day simple moving average is $5.60. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The company has a market cap of $581.83 million, a PE ratio of -55.08 and a beta of 1.93. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50.

Valneva (NASDAQ:VALN) last issued its earnings results on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The firm had revenue of $56.48 million during the quarter, compared to analysts’ expectations of $55.64 million. Equities analysts anticipate that Valneva will post 0.13 EPS for the current year.

Institutional Trading of Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new stake in Valneva SE (NASDAQ:VALN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,244 shares of the company’s stock, valued at approximately $84,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.